Zacks Investment Research on MSN4h
BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA ClearanceBeam Therapeutics Inc. BEAM announced that the FDA has cleared the investigational new drug (IND) application to begin ...
Beam Therapeutics BEAM has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives ...
The field of gene editing recently got a major boost from Massachusetts-based Beam Therapeutics, and the company’s Durham ...
Beam Therapeutics (BEAM) announced that the FDA has cleared the investigational new drug application for BEAM-302 for the treatment of alpha-1 ...
Zacks Investment Research on MSN1d
Beam Therapeutics (BEAM) Down 21.4% Since Last Earnings Report: Can It Rebound?A month has gone by since the last earnings report for Beam Therapeutics Inc. (BEAM). Shares have lost about 21.4% in that time frame, underperforming the S&P 500. Will the recent negative trend ...
Prime Medicine and Beam Therapeutics had common origins in gene editing. Now they're both pursuing treatments for the same ...
Beam Therapeutics reported promising Phase 1/2 data for BEAM-302, demonstrating durable gene correction for AATD. See why I ...
EDT Cathie Wood’s ARK Investment buys 143K shares of Beam Therapeutics (BEAM) todayLight Up your Portfolio with Spark:Easily identify ...
Research analysts at Leerink Partnrs lifted their Q1 2025 earnings estimates for shares of Beam Therapeutics in a research ...
Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...
Research analysts at Cantor Fitzgerald raised their FY2025 earnings per share estimates for shares of Beam Therapeutics in a research report issued on Wednesday, March 12th. Cantor Fitzgerald analyst ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback